{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000007","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.573965+00:00","generated_at":"2026-06-06T09:54:37.255564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25","bullets":["Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).","Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).","Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.","Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.","FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000007","json":"https://secwatch.observer/filing/0001551152-24-000007.json","markdown":"https://secwatch.observer/filing/0001551152-24-000007.md","text":"https://secwatch.observer/filing/0001551152-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/0001551152-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/abbv-20240202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:54:37.255564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa79f9790b2bebdbe00f4ec4461214fcd98db5c5","claim":"AbbVie Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $14.301 billion, EPS $2.79. Guidance reaffirmed.","evidence_excerpt":"These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense • Delivers Fourth-Quarter Net Revenues of $14.301 Billion, a Decrease of 5.4 Percent • Announced Definitive Transaction Agreements to Acquire ImmunoGen and Cerevel Therapeutics, Strengthening AbbVie’s Oncology and Neuroscience","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/0001551152-24-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$14.301 billion"},{"label":"EPS","value":"$2.79"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}